ReviewJournal of clinical oncology : official journal of the American Society of Clinical Oncology2009
Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.
Review in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03871790 (Peptide-based Immunization for Colon- and Pancreas-carcinoma), which is not on this map. Cited by 113 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Peptide-based Immunization for Colon- and Pancreas-carcinoma (PICOP-GLOBAL): An International, Multicenter Protocol
Who cites it
113 citing papers in PubMed, 6 syntheses or guidelines pooled it, 249 citations in OpenAlex.
- Prognostic Implications of Intratumoral and Peritumoral Infiltrating Lymphocytes in Pancreatic Ductal Adenocarcinoma.Current oncology (Toronto, Ont.) · 2021Pooled it
- Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.The Lancet. Oncology · 2018Pooled it
- Pooled it
- A Bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer.PloS one · 2014Pooled it
- A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.Pancreas · 2013Pooled it
- Pancreatic adenocarcinoma.Journal of the National Comprehensive Cancer Network : JNCCN · 2010Guideline
- Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma.Cancer medicine · 2023Trial
- Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer.Medical molecular morphology · 2019Trial
- Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas.British journal of cancer · 2012Trial
- A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer.Investigational new drugs · 2012Trial
- Trial
- Pancreatic Cancer KRAS Breakthrough: Drug Graveyard No More.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- A ternary association of KRas, EphA2, and integrins controls PDAC cell behavior.The Journal of biological chemistry · 2026Article
- Cost-effectiveness analysis of palliative treatment for periampullary cancer: a comparison of surgical and endoscopic approaches.Surgical endoscopy · 2026Article
- Analysis of the relationship between immunological microenvironment and prognosis in pancreatic cancer.American journal of cancer research · 2026Article
- PXMP2 inhibits tumor stemness and immune infiltration in hepatocellular carcinoma based on stemness risk.Discover oncology · 2025Article
- Value of [European journal of nuclear medicine and molecular imaging · 2025Article
- Factors Influencing Immunotherapy Utilization in Stage IV Pancreatic Cancer: Impact of Race and Socioeconomics in the U.S.Journal of gastrointestinal cancer · 2024Article
- Modeling Overall Survival in Patients With Pancreatic Cancer From a Pooled Analysis of Phase II Trials.Cancer medicine · 2024Article
- Cancer Stem Cells in Carcinogenesis and Potential Role in Pancreatic Cancer.Current stem cell research & therapy · 2024Review
53 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
20 authors at 1 institution in 1 country.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer mortality, despite significant improvements in diagnostic imaging and operative mortality rates. The 5-year survival rate remains less than 5% because of microscopic or gross metastatic disease at time of diagnosis. The Clinical Trials Planning Meeting in pancreatic cancer was convened by the National Cancer Institute's Gastrointestinal Cancer Steering Committee to discuss the integration of basic and clinical knowledge in the design of clinical trials in PDAC. Major emphasis was placed on the enhancement of research to identify and validate the relevant targets and molecular pathways in PDAC, cancer stem cells, and the microenvironment. Emphasis was also placed on developing rational combinations of targeted agents and the development of predictive biomarkers to assist selection of patient subsets. The development of preclinical tumor models that are better predictive of human PDAC must be supported with wider availability to the research community. Phase III clinical trials should be implemented only if there is a meaningful clinical signal of efficacy and safety in the phase II setting. The emphasis must therefore be on performing well-designed phase II studies with uniform sets of basic entry and evaluation criteria with survival as a primary endpoint. Patients with either metastatic or locally advanced PDAC must be studied separately.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.